Korean J Pancreas Biliary Tract.
2021 Oct;26(4):233-240. 10.15279/kpba.2021.26.4.233.
Novel Drug Screening Platform: Tumor Organoid
- Affiliations
-
- 1Laboratory of Cell Biology, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
- 2Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea
- 3Korean Cell Line Bank, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
- 4Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, Korea
- KMID: 2522024
- DOI: http://doi.org/10.15279/kpba.2021.26.4.233
Abstract
- Pancreatic ductal adenocarcinoma (PDAC) is known to be one of the most lethal cancers among all cancer types, with a relative 5-year survival rate of less than 8%. Currently, surgery is the only probable curative treatment for PDAC which is available for only 10-15% of the patients diagnosed with the cancer. Organoids resemble the original tissue in morphology and function with self-organizing capacity. Organoids can be cultured with high effectiveness from individual patient derived tumor tissue which makes them an extremely fitting model for translational uses and the improvement of personalized cancer medicine. Before personalized medicine based on organoids can be applied in the clinic, the improvement of drug screening platforms in terms of sensitivity and robustness is necessary.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Preclinical investigation of patient-derived cervical cancer organoids for precision medicine
- Sebaceous Carcinoma and Basal Cell Epithelioma Developed in Organoid Nevus
- Establishment of Patient-Derived Gastric Cancer Organoid Model From Tissue Obtained by Endoscopic Biopsies
- Current Challenges Associated with the Use of Human Induced Pluripotent Stem Cell-Derived Organoids in Regenerative Medicine
- Essential Guidelines for Manufacturing and Application of Organoids
